« If You're Not A Chemist - What Next? |
| Resveratrol (SRT501): Buy Now - Why Wait? »
August 12, 2010
MannKind and Seaside 88?
Readers may remember Generex, the company that's developing a buccal insulin spray. I'm not sold on their technology or their prospects, to put it mildly. In this post I took a look at the investment outfit that did a stock transaction with the company, and found them not to my taste, either.
Well. . .now to MannKind. They've been developing an inhaled insulin formulation (not a buccal spray, I hasten to add) for a long time now. Everyone who's ever worked in the area has had to be in it for the long haul, as the Pfizer/Exubera story will show. It has been long, and it has been expensive, and there have been worries that MannKind might not have enough money to stay the course. They've been seeking a partner for some time now.
Back in March the company got a response from the FDA about the prospects for the drug, which had been delayed. The agency has recently accepted the company's NDA resubmission, with a decision due by the end of the year.
But now comes news that the company is doing a stock-swap deal involving Seaside 88. Given how Seaside 88 looks on close inspection (see that link in the first paragraph), I find it hard to imagine that they'd be anyone's first choice for financing. I have no stock or option position in MannKind - long or short. But if I were long the company, this news would not be making me happy.
+ TrackBacks (0) | Category: Business and Markets | Diabetes and Obesity
POST A COMMENT
- RELATED ENTRIES
- Sydney Brenner on the State of Science
- A Bit More Realism in Consulting
- Out to Illinois
- A Call To Rein In Phase III Trials
- Computational Nirvana
- A Close Look at Receptor Signaling
- The Instructive Case of Galena Biopharma
- Changes in Papers